[{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"e04f5494-d279-4e73-86ac-66647b597c64","acronym":"","url":"https://clinicaltrials.gov/study/NCT05757492","created_at":"2023-03-07T18:02:53.388Z","updated_at":"2024-07-02T16:35:18.481Z","phase":"Phase 1/2","brief_title":"Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05757492","lead_sponsor":"Coherus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • MET mutation • ROS1 mutation","tags":["EGFR • PD-L1 • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • MET mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • JS006"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 04/26/2023","start_date":" 04/26/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-02-20"},{"id":"e68d2a21-c443-4058-9176-91b7dbc528d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03274479","created_at":"2021-01-18T16:10:19.023Z","updated_at":"2024-07-02T16:35:20.103Z","phase":"Phase 1","brief_title":"PBF-1129 in Patients With NSCLC","source_id_and_acronym":"NCT03274479","lead_sponsor":"Palobiofarma SL","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK mutation • ROS1 mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PBF-1129"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-02-09"},{"id":"5ac6e248-8ceb-4558-800b-74838c401239","acronym":"","url":"https://clinicaltrials.gov/study/NCT02955290","created_at":"2021-01-18T14:31:09.469Z","updated_at":"2024-07-02T16:35:29.892Z","phase":"Phase 1/2","brief_title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","source_id_and_acronym":"NCT02955290","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • KRAS • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation • ROS1 mutation","tags":["PD-L1 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 12/22/2016","start_date":" 12/22/2016","primary_txt":" Primary completion: 12/09/2027","primary_completion_date":" 12/09/2027","study_txt":" Completion: 12/09/2027","study_completion_date":" 12/09/2027","last_update_posted":"2023-11-08"},{"id":"277cef5a-ecd7-472f-ac18-a91f7891a25f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02595866","created_at":"2021-01-18T12:35:54.152Z","updated_at":"2024-07-02T16:35:30.462Z","phase":"Phase 1","brief_title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","source_id_and_acronym":"NCT02595866","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • CD4","pipe":" | ","alterations":" BRAF V600 • ALK mutation • ROS1 mutation","tags":["PD-L1 • BRAF • ALK • ROS1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/04/2016","start_date":" 04/04/2016","primary_txt":" Primary completion: 10/04/2023","primary_completion_date":" 10/04/2023","study_txt":" Completion: 10/11/2024","study_completion_date":" 10/11/2024","last_update_posted":"2023-11-03"},{"id":"7b581477-ebf0-4026-ad4e-d6537f45d18d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02426658","created_at":"2021-01-18T11:36:29.773Z","updated_at":"2024-07-02T16:35:33.802Z","phase":"Phase 2","brief_title":"Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3","source_id_and_acronym":"NCT02426658","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ROS1 mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/19/2018","primary_completion_date":" 04/19/2018","study_txt":" Completion: 10/07/2022","study_completion_date":" 10/07/2022","last_update_posted":"2023-10-12"},{"id":"ad93c732-ba36-4a28-a4d6-bf2813bd5cbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT06055166","created_at":"2023-09-26T16:12:26.789Z","updated_at":"2024-07-02T16:35:35.791Z","phase":"Phase 2","brief_title":"A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors","source_id_and_acronym":"NCT06055166","lead_sponsor":"Chongqing University Cancer Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • ROS1 mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • capecitabine • AiRuiYi (fluzoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2023-09-26"},{"id":"e328c5fa-3583-48bf-8faa-651929d4dea6","acronym":"LIST","url":"https://clinicaltrials.gov/study/NCT04500535","created_at":"2021-01-18T21:33:30.976Z","updated_at":"2024-07-02T16:35:47.455Z","phase":"","brief_title":"A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy","source_id_and_acronym":"NCT04500535 - LIST","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • EGFR mutation • BRAF mutation • MET mutation • ALK translocation • ROS1 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • EGFR mutation • BRAF mutation • MET mutation • ALK translocation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 698","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 09/15/2025","primary_completion_date":" 09/15/2025","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2023-05-22"},{"id":"565d9c7a-c834-4faa-9d14-ac630ac812dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05645315","created_at":"2022-12-09T14:57:48.849Z","updated_at":"2024-07-02T16:35:59.356Z","phase":"Phase 1/2","brief_title":"Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05645315","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR • ALK • ROS1 • HAVCR2","pipe":" | ","alterations":" PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation","tags":["EGFR • ALK • ROS1 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Andewei (benmelstobart) • TQB2618"],"overall_status":"Recruiting","enrollment":" Enrollment 127","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-12-09"},{"id":"125a7b91-8db5-46b8-a5c2-7bd50f1bdda9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05116618","created_at":"2021-11-12T00:10:03.219Z","updated_at":"2024-07-02T16:36:03.722Z","phase":"","brief_title":"Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged","source_id_and_acronym":"NCT05116618","lead_sponsor":"University of Colorado, Denver","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ALK mutation • ROS1 rearrangement • ROS1 mutation • ALK amplification","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ALK mutation • ROS1 rearrangement • ROS1 mutation • ALK amplification"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/06/2022","start_date":" 01/06/2022","primary_txt":" Primary completion: 09/15/2022","primary_completion_date":" 09/15/2022","study_txt":" Completion: 09/15/2022","study_completion_date":" 09/15/2022","last_update_posted":"2022-09-21"},{"id":"186e697f-05ba-4731-9903-b2fbefc7858b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03868423","created_at":"2021-01-18T19:04:37.636Z","updated_at":"2024-07-02T16:36:16.937Z","phase":"Phase 2","brief_title":"Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers","source_id_and_acronym":"NCT03868423","lead_sponsor":"Sameek Roychowdhury","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2022-02-18"},{"id":"7eea64d9-6db5-49b3-a7cb-2ebce35952c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04846452","created_at":"2021-04-15T12:53:08.701Z","updated_at":"2024-07-02T16:36:26.498Z","phase":"Phase 2","brief_title":"Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC","source_id_and_acronym":"NCT04846452","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK mutation • ROS1 mutation","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Focus V (anlotinib) • Tyvyt (sintilimab) • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2021-08-12"},{"id":"1439e0db-e271-4737-9775-b56261959408","acronym":"SNK_ASTER","url":"https://clinicaltrials.gov/study/NCT04872634","created_at":"2021-05-04T11:52:45.506Z","updated_at":"2024-07-02T16:36:27.603Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment","source_id_and_acronym":"NCT04872634 - SNK_ASTER","lead_sponsor":"NKMAX Co., Ltd.","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • ROS1 mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • carboplatin • gemcitabine • troculeucel (SNK01)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 05/26/2023","primary_completion_date":" 05/26/2023","study_txt":" Completion: 05/26/2023","study_completion_date":" 05/26/2023","last_update_posted":"2021-07-21"},{"id":"ce3736cc-4e31-45d3-bb0f-4bd380fee0e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03636685","created_at":"2021-01-18T17:51:27.412Z","updated_at":"2024-07-02T16:37:07.770Z","phase":"Phase 1/2","brief_title":"Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC","source_id_and_acronym":"NCT03636685","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Focus V (anlotinib) • pemetrexed"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 08/14/2019","primary_completion_date":" 08/14/2019","study_txt":" Completion: 08/14/2020","study_completion_date":" 08/14/2020","last_update_posted":"2018-08-17"},{"id":"b6a1bc66-b782-4dcd-b05d-62749356f176","acronym":"","url":"https://clinicaltrials.gov/study/NCT02946216","created_at":"2021-01-18T14:28:16.643Z","updated_at":"2024-07-02T16:37:28.172Z","phase":"","brief_title":"ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC","source_id_and_acronym":"NCT02946216","lead_sponsor":"First People's Hospital of Hangzhou","biomarkers":" EGFR • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR wild-type • ALK mutation • MET mutation • ROS1 mutation","tags":["EGFR • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK mutation • MET mutation • ROS1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2016-10-27"}]